Latest News - Pfizer
Top Corporates Hub
Pfizer
Where is Pfizer Inc. (PFE) Headed?
19.02.2026 14:53
Pfizer Inc. (NYSE:PFE) is one of the best immunotherapy stocks to buy according to hedge funds. On February 12, Daiwa downgraded Pfizer Inc. (NYSE:PFE) to Neutral from Outperform and set a $27 price target. In another development, Pfizer Inc. (NYSE:PFE) announced on February 6 that the U.S. Food and Drug Administration accepted and granted Priority […]
Top High-Yield Stocks to Double Up on Right Now
19.02.2026 14:34
If you are looking for high-yield stocks, these two turnaround stories offer yield and green shoots, suggesting better times are ahead.
Walmart earnings, Fed meeting minutes, Zuckerberg's testimony and more in Morning Squawk
19.02.2026 08:20
Here are five key things investors need to know to start the trading day.
Pfizer Colorectal Cancer Trial Win Adds Weight To Oncology Turnaround Story
18.02.2026 14:10
Pfizer (NYSE:PFE) reported positive topline results from its pivotal BREAKWATER trial. The study evaluated a BRAFTOVI based combination in previously untreated metastatic colorectal cancer with a BRAF V600E mutation. Results showed a clinically meaningful improvement in progression free survival for patients in the first line setting. The update reflects progress toward a potential new regulatory filing for this colorectal cancer indication. For Pfizer, which has a broad portfolio across...
Pfizer (PFE) Valuation Check After Recent Share Price Rebound And Mixed Earnings Signals
18.02.2026 13:08
Why Pfizer (PFE) is on investors’ radar today Pfizer (PFE) is drawing attention after recent trading left the shares at a last close of $27.37, with returns of 6.7% over the past month and 10.0% over the past 3 months. See our latest analysis for Pfizer. Pfizer’s recent move to a US$27.37 share price comes after a 6.7% 1 month share price return and a 10.0% 3 month share price return. Its 1 year total shareholder return of 14.85% contrasts with a 23.18% total shareholder return decline over...
FDA agrees to review Moderna’s mRNA flu vaccine application in a reversal
18.02.2026 11:17
The FDA is slated to make a decision on the flu shot on Aug. 5, which will allow Moderna to make the vaccine available for the upcoming influenza season.
Fallopian Tube Cancer Market Research Report 2026: AstraZeneca, GlaxoSmithKline, Pfizer and Roche Expand Portfolios and Invest in Novel Therapeutics & Companion Diagnostics - Forecasts 2025-2035
18.02.2026 09:26
Fallopian tube cancer, a rare gynecologic cancer, is gaining awareness due to its potential origin for many high-grade serous ovarian cancers. New diagnostics improve early detection and treatment, boosting patient outcomes. Symptoms are often subtle, leading to underdiagnosis and treatment delays. The fallopian tube cancer market is driven by genetic testing demand, BRCA mutation screening, and advancements in targeted therapies like PARP inhibitors. Despite challenges, including high treatment
Pfizer Trial Updates Test Investor Views On Pipeline And Valuation
17.02.2026 13:09
Pfizer (NYSE:PFE) reported positive topline Phase 3 results from its BREAKWATER oncology trial in metastatic colorectal cancer with BRAF V600E mutation. The company also announced Phase 2b data for its once monthly, ultra long acting GLP 1 obesity drug candidate. The FDA granted Priority Review to Pfizer’s supplemental Biologics License Application for HYMPAVZI, seeking expanded use in hemophilia patients. For you as an investor, these updates touch three areas where Pfizer is highly...
ViiV Healthcare showcases long-acting HIV innovation and potential of ultra long-acting pipeline, including new data for first third-generation integrase inhibitor at CROI 2026
17.02.2026 13:00
LONDON, February 17, 2026--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced data presentations from its innovative HIV treatment and prevention portfolio and integrase inhibitor (INSTI)-led pipeline at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado from 22-25 February.
Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer
17.02.2026 11:45
NEW YORK, February 17, 2026--Pfizer Inc. (NYSE: PFE) today announced positive topline progression-free (PFS) survival results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. The BRAFTOVI regimen demonstrated a statistically si
Daiwa Downgrades Pfizer (PFE) to Neutral Following Full-Year 2025 Earnings
14.02.2026 06:28
Pfizer Inc. (NYSE:PFE) is one of the most promising low-cost stocks to buy now. On February 10, Bernstein maintained its Market Perform rating and $30 price target for Pfizer following a Q4 2o25 earnings report that exceeded expectations with $17.6 billion in revenue and $0.66 EPS. Despite strong financial results and a raised 2025 EPS […]
Pfizer Obesity And Hemophilia Advances Spark Fresh Interest In Valuation
13.02.2026 15:13
Pfizer reported positive Phase 2b results for its monthly GLP-1 obesity drug candidate PF-3944, with plans to run more than 20 clinical trials, including several focused on this asset. The FDA granted Priority Review for expanded use of HYMPAVZI in hemophilia A or B, potentially widening its eligible patient pool. These updates highlight fresh developments in obesity and hematology that go beyond routine product updates or earnings headlines. For investors tracking NYSE:PFE, these pipeline...
Is Pfizer Inc. (PFE) One of the Best Medical Research Stocks to Buy According to Hedge Funds?
13.02.2026 14:57
Pfizer Inc. (NYSE:PFE) is one of the best medical research stocks to buy according to hedge funds. Pfizer Inc. (NYSE:PFE) announced on February 6 that the U.S. Food and Drug Administration accepted and granted Priority Review for its supplemental Biologics License Application for HYMPAVZI® for the expansion of the approved indication to include treatment of […]
Meet the 6.3% Yield Dividend Stock That Could Soar in 2026
13.02.2026 11:52
Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally.
Pfizer Hemophilia And Obesity Updates Reshape Growth And Valuation Outlook
12.02.2026 04:30
Pfizer (NYSE:PFE) received FDA Priority Review to expand HYMPAVZI to younger hemophilia patients and those with inhibitors. The company reported positive topline phase 2b results for its obesity drug candidate PF-3944 and plans to start multiple phase 3 trials in 2026. Both updates relate to large areas of unmet medical need in hemophilia and obesity care. For investors watching NYSE:PFE, these clinical updates arrive with the stock at $27.73 and a value score of 5. Over the past year, the...
Pfizer Pipeline Progress And Partnerships Tested Against Depressed Valuation
10.02.2026 20:09
Pfizer (NYSE:PFE) received FDA Priority Review for an expanded use of HYMPAVZI in younger and inhibitor-experienced hemophilia patients. Partnered antifungal Cresemba reached sales in Asia Pacific that triggered a milestone payment to Pfizer. Pfizer joined the BaseLaunch biotech incubator as a partner to work with early stage drug developers. Pfizer enters this news cycle with its shares at $27.05 and a mixed return profile, with a 13.6% gain over the past year, a 25.9% decline over three...
Pfizer Inc. (PFE) Announces FDA’s Grant of Priority Review for HYMPAVZI® (marstacimab) sBLA
10.02.2026 15:39
Pfizer Inc. (NYSE:PFE) is one of the best healthcare stocks under $50 to invest in. Pfizer Inc. (NYSE:PFE) announced on February 6 that the U.S. Food and Drug Administration accepted and granted Priority Review for its supplemental Biologics License Application for HYMPAVZI® for the expansion of the approved indication to include treatment of hemophilia A […]
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
10.02.2026 14:00
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer Becomes Newest Partner Added to BaseLaunch's Biotech Venture Incubator
10.02.2026 12:59
BaseLaunch, a platform partnering with scientists and entrepreneurs to launch, fund, and build early biotech ventures, announced today the pharmaceutical giant Pfizer has joined the Basel-based incubator, bringing the total number of leading pharma company partners to seven.
5 Revealing Analyst Questions From Pfizer’s Q4 Earnings Call
10.02.2026 05:37
Pfizer closed the fourth quarter with revenue ahead of Wall Street expectations, but the market reacted negatively due to a combination of year-over-year sales decline and shrinking operating margins. Management explained that the drop in COVID-19 product demand weighed heavily on overall results, while non-COVID products delivered solid operational growth. CEO Albert Bourla cited the impact of a “narrow recommendation for vaccines in the US” as a driver behind lower COVID product sales and high